NO20052580L - Blandinger for behandling av infeksjon av Flavivirida viruser - Google Patents

Blandinger for behandling av infeksjon av Flavivirida viruser

Info

Publication number: NO20052580L
Authority: NO; Norway
Prior art keywords: flavivirida; viruses; infection; compounds; treatment
Prior art date: 2002-10-29

Application number

NO20052580A

Other languages

English (en)

Norwegian (no)

Other versions

NO20052580D0 (no

Inventor

Lisette Lagac

Daniel Lamarre

Original Assignee

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-10-29

Filing date

2005-05-27

Publication date

2005-07-20

2005-05-27 Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

2005-05-27 Publication of NO20052580D0 publication Critical patent/NO20052580D0/no

2005-07-20 Publication of NO20052580L publication Critical patent/NO20052580L/no

Links

241000700605 Viruses Species 0.000 title abstract 2
150000001875 compounds Chemical class 0.000 title abstract 2
208000015181 infectious disease Diseases 0.000 title 1
241000124008 Mammalia Species 0.000 abstract 2
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 2
HFFXLYHRNRKAPM-UHFFFAOYSA-N 2,4,5-trichloro-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C(=CC(Cl)=C(Cl)C=2)Cl)=N1 HFFXLYHRNRKAPM-UHFFFAOYSA-N 0.000 abstract 1
125000000753 cycloalkyl group Chemical group 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
125000000335 thiazolyl group Chemical group 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Public Health (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Virology (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Peptides Or Proteins (AREA)

NO20052580A 2002-10-29 2005-05-27 Blandinger for behandling av infeksjon av Flavivirida viruser NO20052580L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US42190002P	2002-10-29	2002-10-29
US44276903P	2003-01-27	2003-01-27
PCT/CA2003/001634 WO2004039833A1 (en)	2002-10-29	2003-10-24	Composition for the treatment of infection by flaviviridae viruses

Publications (2)

Publication Number	Publication Date
NO20052580D0 NO20052580D0 (no)	2005-05-27
NO20052580L true NO20052580L (no)	2005-07-20

Family

ID=32233460

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20052580A NO20052580L (no)	2002-10-29	2005-05-27	Blandinger for behandling av infeksjon av Flavivirida viruser

Country Status (13)

Country	Link
US (1)	US20050159345A1 (pl)
EP (1)	EP1558633A1 (pl)
JP (1)	JP2006517196A (pl)
KR (1)	KR20050061592A (pl)
AU (1)	AU2003275852A1 (pl)
BR (1)	BR0315781A (pl)
CA (1)	CA2498642A1 (pl)
EA (1)	EA200500610A1 (pl)
EC (1)	ECSP055815A (pl)
MX (1)	MXPA05004604A (pl)
NO (1)	NO20052580L (pl)
PL (1)	PL376409A1 (pl)
WO (1)	WO2004039833A1 (pl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ335276A (en)	1996-10-18	2000-09-29	Vertex Pharma	Inhibitors of serine proteases, particularly hepatitis C virus (HCV) NS3 (Non Structural Protein 3) protease
US6867185B2 (en) *	2001-12-20	2005-03-15	Bristol-Myers Squibb Company	Inhibitors of hepatitis C virus
US7176208B2 (en) *	2003-04-18	2007-02-13	Enanta Pharmaceuticals, Inc.	Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
EP1673385B1 (en) *	2003-09-22	2011-03-02	Boehringer Ingelheim International GmbH	Macrocyclic peptides active against the hepatitis c virus
US7491794B2 (en)	2003-10-14	2009-02-17	Intermune, Inc.	Macrocyclic compounds as inhibitors of viral replication
WO2005070955A1 (en)	2004-01-21	2005-08-04	Boehringer Ingelheim International Gmbh	Macrocyclic peptides active against the hepatitis c virus
ES2336009T3 (es)	2004-01-30	2010-04-07	Medivir Ab	Inhibidores de la ns-3 serina proteasa del vhc.
PE20070211A1 (es)	2005-07-29	2007-05-12	Medivir Ab	Compuestos macrociclicos como inhibidores del virus de hepatitis c
CA2618682C (en)	2005-08-12	2011-06-21	Boehringer Ingelheim International Gmbh	Viral polymerase inhibitors
AR055395A1 (es)	2005-08-26	2007-08-22	Vertex Pharma	Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7816348B2 (en)	2006-02-03	2010-10-19	Boehringer Ingelheim International Gmbh	Viral polymerase inhibitors
WO2008019477A1 (en)	2006-08-17	2008-02-21	Boehringer Ingelheim International Gmbh	Viral polymerase inhibitors
AU2007286754A1 (en) *	2006-08-25	2008-02-28	Viropharma Incorporated	Identification and characterization of HCV replicon variants with reduced susceptibility to HCV-796, and methods related thereto
WO2009018657A1 (en)	2007-08-03	2009-02-12	Boehringer Ingelheim International Gmbh	Viral polymerase inhibitors
CA2708150A1 (en)	2007-12-05	2009-06-18	Enanta Pharmaceuticals, Inc.	Fluorinated tripeptide hcv serine protease inhibitors
EP2234977A4 (en)	2007-12-19	2011-04-13	Boehringer Ingelheim Int	VIRAL POLYMERASE INHIBITORS
EP2334680A2 (en) *	2008-08-20	2011-06-22	Sequoia Pharmaceuticals, Inc.	Hcv protease inhibitors
UY32099A (es)	2008-09-11	2010-04-30	Enanta Pharm Inc	Inhibidores macrocíclicos de serina proteasas de hepatitis c
KR20110116136A (ko)	2009-01-07	2011-10-25	싸이넥시스, 인크.	Ｈｃｖ 및 ｈｉｖ 감염의 치료에 사용하기 위한 사이클로스포린 유도체
CA2761650C (en)	2009-05-13	2015-05-26	Enanta Pharmaceuticals, Inc.	Macrocyclic compounds as hepatitis c virus inhibitors
US8232246B2 (en)	2009-06-30	2012-07-31	Abbott Laboratories	Anti-viral compounds
JP2013511561A (ja) *	2009-11-24	2013-04-04	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｃ型肝炎阻害化合物
WO2011063502A1 (en) *	2009-11-24	2011-06-03	Boehringer Ingelheim International Gmbh	Hepatitis c inhibitor compounds
TWI523658B (zh)	2010-09-21	2016-03-01	安塔製藥公司	巨環脯胺酸衍生之ｈｃｖ絲胺酸蛋白酶抑制劑
KR20140003521A (ko)	2010-12-30	2014-01-09	이난타 파마슈티칼스, 인코포레이티드	페난트리딘 매크로사이클릭 ｃ형 간염 세린 프로테아제 억제제
CN103534256B (zh)	2010-12-30	2016-08-10	益安药业	大环丙型肝炎丝氨酸蛋白酶抑制剂
US10201584B1 (en)	2011-05-17	2019-02-12	Abbvie Inc.	Compositions and methods for treating HCV
AR091279A1 (es) *	2012-06-08	2015-01-21	Gilead Sciences Inc	Inhibidores macrociclicos de virus flaviviridae
SI2859009T1 (sl) *	2012-06-08	2017-12-29	Gilead Sciences, Inc.	Makrociklični inhibitorji flaviviridae virusov
IN2014MN02652A (pl)	2012-06-08	2015-08-21	Gilead Sciences Inc
KR101446049B1 (ko) *	2013-01-14	2014-10-01	전남대학교산학협력단	뎅기 바이러스 관련 질환의 치료 또는 예방용 조성물
WO2015103490A1 (en)	2014-01-03	2015-07-09	Abbvie, Inc.	Solid antiviral dosage forms
JP7497790B2 (ja) *	2019-12-27	2024-06-11	国立大学法人北海道大学	豚コレラの治療及び／又は予防剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6608027B1 (en) *	1999-04-06	2003-08-19	Boehringer Ingelheim (Canada) Ltd	Macrocyclic peptides active against the hepatitis C virus
UA74546C2 (en) *	1999-04-06	2006-01-16	Boehringer Ingelheim Ca Ltd	Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US6867185B2 (en) *	2001-12-20	2005-03-15	Bristol-Myers Squibb Company	Inhibitors of hepatitis C virus
CA2369711A1 (en) *	2002-01-30	2003-07-30	Boehringer Ingelheim (Canada) Ltd.	Macrocyclic peptides active against the hepatitis c virus
US6828301B2 (en) *	2002-02-07	2004-12-07	Boehringer Ingelheim International Gmbh	Pharmaceutical compositions for hepatitis C viral protease inhibitors

2003
- 2003-10-16 US US10/687,204 patent/US20050159345A1/en not_active Abandoned
- 2003-10-24 PL PL03376409A patent/PL376409A1/pl not_active Application Discontinuation
- 2003-10-24 KR KR1020057007589A patent/KR20050061592A/ko not_active Withdrawn
- 2003-10-24 BR BR0315781-4A patent/BR0315781A/pt not_active Application Discontinuation
- 2003-10-24 CA CA002498642A patent/CA2498642A1/en not_active Abandoned
- 2003-10-24 AU AU2003275852A patent/AU2003275852A1/en not_active Abandoned
- 2003-10-24 EA EA200500610A patent/EA200500610A1/ru unknown
- 2003-10-24 MX MXPA05004604A patent/MXPA05004604A/es not_active Application Discontinuation
- 2003-10-24 EP EP03809665A patent/EP1558633A1/en not_active Withdrawn
- 2003-10-24 JP JP2005501790A patent/JP2006517196A/ja active Pending
- 2003-10-24 WO PCT/CA2003/001634 patent/WO2004039833A1/en not_active Ceased
2005
- 2005-05-24 EC EC2005005815A patent/ECSP055815A/es unknown
- 2005-05-27 NO NO20052580A patent/NO20052580L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
AU2003275852A1 (en)	2004-05-25
KR20050061592A (ko)	2005-06-22
CA2498642A1 (en)	2004-05-13
US20050159345A1 (en)	2005-07-21
ECSP055815A (es)	2005-08-11
EP1558633A1 (en)	2005-08-03
WO2004039833A1 (en)	2004-05-13
BR0315781A (pt)	2005-09-13
NO20052580D0 (no)	2005-05-27
JP2006517196A (ja)	2006-07-20
PL376409A1 (pl)	2005-12-27
EA200500610A1 (ru)	2005-10-27
MXPA05004604A (es)	2005-07-13

Legal Events

Date	Code	Title	Description
2006-05-29	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
EA200500610A1 (ru)	2005-10-27	Композиция для лечения инфекции, вызываемой вирусами семейств flaviviridae
EA201101492A1 (ru)	2012-09-28	Аналоги тиофена для лечения или предупреждения флавивирусных инфекций
NO20060706L (no)	2006-02-14	Inhibitorer av serinproteaser, spesielt HCV NS3-NS4A-protease
NO20062101L (no)	2006-07-05	Serinproteaseinhibitorer, spesielt hcv ns3-ns4a-protease
NO20075723L (no)	2008-02-05	Tiazolforbindelser og fremgangsmater for anvendelse
NO20043591L (no)	2004-08-27	Makrosykliske peptider aktive mot hepatitt C virus
NO20091889L (no)	2009-06-17	Inhibitorer av spiroketon acetyl-CoA karboksylase
BRPI0508867A (pt)	2007-09-04	processo para a preparação de compostos macrocìclicos
NO20063382L (no)	2006-09-20	Nye kinolinderivater
NO20065736L (no)	2007-02-08	Substituerte arylacyltioureaer og relaterte forbindelser; Inhibitorer av viral reproduksjon
NO20062370L (no)	2006-07-18	Amidderivater
NO20091704L (no)	2009-07-27	Inhibitorer av hepatitt C virus
NO20091706L (no)	2009-07-21	Inhibitorer av hepatitt C virus
NO20091707L (no)	2009-05-29	Inhibitorer av hepatitt C virus
NO20073357L (no)	2007-08-30	5-karboksamid substituerte tiazol derivater som reagerer med ionekanaler, i saerdeleshet med ionekanaler fra Kv familien
NO20064251L (no)	2006-11-22	Benzamidazolderivater og anvendelse derav
EA200400022A1 (ru)	2004-06-24	Соединения и способы лечения или предупреждения инфекций flavivirus
NO20072286L (no)	2007-05-02	Hemming av HCV NS3-NS4A-protease
EA200900156A1 (ru)	2009-06-30	Пиридазиновое соединение (варианты), способ его получения (варианты), способ лечения или профилактики инфекционного вирусного гепатита с с его помощью, композиция и лекарственное средство на его основе
WO2008021928A3 (en)	2008-03-27	Hepatitis c virus inhibitors
ATE447573T1 (de)	2009-11-15	Chinoxalinyl-makrocyclische hepatitis c serin protease-hemmer
GB0612423D0 (en)	2006-08-02	Therapeutic agents
WO2006027628A3 (en)	2006-05-04	Naphthalimide derivatives as antiviral agents
DE60317326D1 (de)	2007-12-20	Phenylalkansäure- und phenyloxyalkansäure-derivate als hppar aktivatore
NO20070258L (no)	2007-01-15	Benzyltriazolonforbindelser som ikke-nukleoside revers transkriptase inhibitorer